Bone Biologics Corp. BBLG
0.50
0.01
2.04%
as of 25 Sep
- Market cap
- $1.4M
- P/E
- 0.0×
Follow BBLG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
8.67 | 16.09 | 13.85 | 19.00 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.99 | 5.63 | 7.28 | 8.46 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 1.05 | 1.04 | 0.89 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.29) | (0.45) | (0.61) | (0.33) | |
Cash per Share |
2.24 | 2.52 | 4.54 | 3.37 | |
Shareholders Equity per Share |
2.18 | 2.60 | 4.58 | 3.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.18 | 2.60 | 4.58 | 3.35 | |
Free Cash Flow |
(0.52) | (0.80) | (0.71) | (0.59) | |
Working Capital |
3.92 | 4.67 | 5.38 | 6.02 | |
Net Current Asset Value |
3.92 | 4.67 | 5.38 | 6.02 | |
| Other line items | |||||
Quick Ratio |
7.89 | 14.67 | 12.77 | 18.09 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.29) | (0.45) | (0.61) | (0.33) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.46 | 0.28 | 0.40 | 0.26 | |
Average Assets |
5.72 | 4.07 | 4.83 | 5.21 | |
Average Common Equity |
5.26 | 3.79 | 4.43 | 4.90 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates